LTS donates 40 trees for the project “Roots for All”
LTS ist participating in the "Roots for All" project in the Neuwied municipal forest with a sustainable donation of 40 trees.
LTS expands into large molecule drug delivery with the acquisition of the Sorrel wearable injection device business
LTS, a leading pharmaceutical technology company announces the signing of the acquisition of the Sorrel wearable injection device business a part of the Eitan Medical Ltd.
Investment in the future:
Ground-breaking ceremony for the new LTS technical centre
Board members of LTS together with the outgoing mayor of the city of Andernach and his successor performed the groundbreaking ceremony for the future LTS Technical centre.
Innovation in drug delivery to transform home-based palliative care
Advances in drugs and medical devices helping to give patients more opportunity to manage their conditions in familiar surroundings.
LTS signs commitment to set near-term and long-term company-wide emission reductions in line with climate science with the SBTi
LTS has also responded to the SBTi’s urgent call for corporate climate action by committing to align with 1.5°C and net-zero through the Business Ambition for 1.5°C campaign.
LTS is now part of the „Initiative Energieeffizienz- und Klimaschutz-Netzwerke”
LTS has decided to participate in an energy efficiency and climate protection network because it enables companies to plan and implement economic investments in energy efficiency on a solid data basis.
The CEO Perspective: Stick to your strategy in turbulent times
In line with recent years, 2022 was anything but plain [...]
LTS and Micron announce collaboration for commercial manufacturing of Micro Array Patch (MAP) technology
LTS LOHMANN Therapie-Systeme AG (LTS) and Micron Biomedical, Inc. (Micron) have entered into a technical transfer and scale-up agreement for Micron´s Micro Array Patch (MAP) technology.
Micro Array Patches – Background and Case Study
Get insight in the development of an Interferon-ß containing MAP (Micro Array Patch) and the performance of two prototypes in a pre-clinical study.
Dr Michael Hoffmann is a new member of the Supervisory Board of LTS LOHMANN Therapie-Systeme AG
Dr. Michael Hoffmann was elected to succeed Oliver Hopp as a new member of the LTS Supervisory Board.